Morepen Laboratories Limited (MOREPENLAB) submits its first U.S. ANDA for Sitagliptin Tablets, enhancing its CDMO capabilities.
Dishman Carbogen Amcis Limited (DCAL) reports Q1FY27 results with net revenue dipping 4.29%, driven by CDMO segment decline.
Sai Life Sciences Limited (SAILIFE) reports Q1 FY27 results with ₹554 crore revenue, up 12% YoY, strong CRO growth and sustained pipeline.
Cohance Lifesciences Limited (COHANCE) reports Q1FY27 financial results, with revenue down 23.1% YoY, expects rebound in H2.
Morepen Laboratories Limited (MOREPENLAB) has initiated commercial supplies under its ₹825 crore CDMO mandate, completing the first ₹50 crore dispatch in Q1F.
Dishman Carbogen Amcis Limited (DCAL) reports a 18.9% revenue increase in Q4 FY26, driven by growth in CDMO and Marketable Molecules segments.
Sai Life Sciences Limited (SAILIFE) reports a 29% revenue increase and a 56% EBITDA rise for FY26, driven by strong execution and strategic investments.